906 related articles for article (PubMed ID: 33540684)
21. RNA m6A methylation promotes the formation of vasculogenic mimicry in hepatocellular carcinoma via Hippo pathway.
Qiao K; Liu Y; Xu Z; Zhang H; Zhang H; Zhang C; Chang Z; Lu X; Li Z; Luo C; Liu Y; Yang C; Sun T
Angiogenesis; 2021 Feb; 24(1):83-96. PubMed ID: 32920668
[TBL] [Abstract][Full Text] [Related]
22. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
23. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
[TBL] [Abstract][Full Text] [Related]
24. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
25. Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma.
Pan Q; Qin F; Yuan H; He B; Yang N; Zhang Y; Ren H; Zeng Y
Cancer Med; 2021 May; 10(9):3139-3152. PubMed ID: 33818013
[TBL] [Abstract][Full Text] [Related]
26. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
[TBL] [Abstract][Full Text] [Related]
27. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
28. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
29. Gene Signatures and Prognostic Values of m6A RNA Methylation Regulators in Ovarian Cancer.
Han X; Liu J; Cheng G; Cui S
Cancer Control; 2020; 27(1):1073274820960460. PubMed ID: 32951457
[TBL] [Abstract][Full Text] [Related]
30. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
31. RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance.
Zhao H; Zhou Q; Shi C; Shao Y; Ni J; Lou J; Wei S
Med Sci Monit; 2021 Oct; 27():e930994. PubMed ID: 34690344
[TBL] [Abstract][Full Text] [Related]
32. The functions and prognostic values of m6A RNA methylation regulators in thyroid carcinoma.
Yu ZH; Feng ST; Zhang D; Cao XC; Yu Y; Wang X
Cancer Cell Int; 2021 Jul; 21(1):385. PubMed ID: 34281544
[TBL] [Abstract][Full Text] [Related]
33. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
Yu ZL; Zhu ZM
Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
[TBL] [Abstract][Full Text] [Related]
35. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis.
Chen M; Wong CM
Mol Cancer; 2020 Feb; 19(1):44. PubMed ID: 32111216
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
Yin T; Zhao L; Yao S
BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
[TBL] [Abstract][Full Text] [Related]
37. m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer.
Zhang C; Liu J; Guo H; Hong D; Ji J; Zhang Q; Guan Q; Ren Q
Bioengineered; 2021 Dec; 12(1):3159-3176. PubMed ID: 34187307
[TBL] [Abstract][Full Text] [Related]
38. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
[TBL] [Abstract][Full Text] [Related]
39. A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients.
Xie S; Wang Y; Huang J; Li G
IET Syst Biol; 2022 Feb; 16(1):1-17. PubMed ID: 34647424
[TBL] [Abstract][Full Text] [Related]
40. Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.
He D; Liao S; Cai L; Huang W; Xie X; You M
BMC Cancer; 2021 May; 21(1):599. PubMed ID: 34034705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
